NextBig3D
Develops India's first commercial 3D bioprinter (TRIVIMA) and bioprinted tissues for pharmaceutical, clinical, and cosmetic R&D, aiming to create lab-grown organs like skin and liver tissues.
- CEO / Founder
- Ratandeep Singh Bansal
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $80K
- Latest Round
- Grant
- Key Investors
- German Tech
Technology & Products
Key Products
TRIVIMA 3D bioprinter; 3D bioprinted skin for R&D; 3D bioprinted liver for pre-clinical testing
Technological Advantage
Proprietary bioprinting technology tailored for cost-sensitive markets; early mover in Indian bioprinting space with TRIVIMA system.
Differentiation
Value Proposition
Provides affordable, customizable 3D bioprinting solutions for developing countries, enabling local production of medical tissues and reducing dependency on imported technologies.
How They Differentiate
Focus on low-cost, customizable solutions for developing countries vs. premium global bioprinters; TRIVIMA targets affordability and local manufacturing.
Market & Competition
Target Customers
Pharmaceutical companies, clinical research organizations, cosmetic research labs, academic institutions
Industry Verticals
Medical; Pharmaceutical; Cosmetic
Competitors
Axolotl Biosciences; CELLINK; Allevi
Growth & Milestones
Growth Metrics
Annual revenue of ₹2.15Cr as of March 31, 2024
Major Milestones
Launched India's first commercial 3D bioprinter (TRIVIMA); Developed 3D bioprinted skin and liver tissues for R&D